ESC 365 - Short dual antiplatelet therapy duration in high bleeding risk patients undergoing PCI for non-ST-elevation acute coronary syndrome

ESC Professional Premium Access

Short dual antiplatelet therapy duration in high bleeding risk patients undergoing PCI for non-ST-elevation acute coronary syndrome

Session: Short and long-term antiplatelet therapy in clinical practice

Topic: Antiplatelet Drugs

Speaker: Doctor D. Cao (Milan, IT)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Doctor Davide Cao

Humanitas University, Milan (Italy)

2 presentations

0 follower

7 more presentations in this session

CYP2C19 loss-of-function alleles and the use of omeprazole or esomeprazole increase the risk of cardiovascular outcomes in patients using clopidogrel - a real-world study

Speaker: Mr M. Ritvos (Helsinki, FI)

Bentracimab demonstrates reversal of antiplatelet effects of ticagrelor: impact of hematocrit and generic versions of ticagrelor in vitro

Speaker: Professor B. Curry (Memphis, US)

Intravenous antiplatelet therapy with cangrelor vs. tirofiban in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention

Speaker: Doctor M. Centore (Salerno, IT)

Comparing dual antiplatelet therapy strategies post-acute coronary syndrome: network meta-analysis

Speaker: Doctor R. Turgeon (Vancouver, CA)

Thirty-days versus standard duration of dual antiplatelet treatment after percutaneous coronary interventions: a systematic review and meta-analysis

Speaker: Doctor A. Apostolos (Athens, GR)

Access the full session

Short and long-term antiplatelet therapy in clinical practice

Speakers: Doctor D. Cao, Mr M. Ritvos, Professor B. Curry, Doctor M. Centore, Doctor R. Turgeon...

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources